Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2015 4
2016 3
2017 2
2018 3
2019 1
2020 3
2021 18
2022 32
2023 39
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.
Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Paskeh MDA, et al. Among authors: entezari m. J Hematol Oncol. 2022 Jun 28;15(1):83. doi: 10.1186/s13045-022-01305-4. J Hematol Oncol. 2022. PMID: 35765040 Free PMC article. Review.
STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response.
Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. Sadrkhanloo M, et al. Among authors: entezari m. Pharmacol Res. 2022 Aug;182:106311. doi: 10.1016/j.phrs.2022.106311. Epub 2022 Jun 15. Pharmacol Res. 2022. PMID: 35716914 Review.
EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions.
Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, Kakavand A, Tavakolpournegari A, Saebfar H, Heidari H, Salimimoghadam S, Entezari M, Taheriazam A, Hushmandi K. Hashemi M, et al. Among authors: entezari m. Biomed Pharmacother. 2022 Nov;155:113774. doi: 10.1016/j.biopha.2022.113774. Epub 2022 Oct 3. Biomed Pharmacother. 2022. PMID: 36271556 Free article. Review.
AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation.
Entezari M, Hashemi D, Taheriazam A, Zabolian A, Mohammadi S, Fakhri F, Hashemi M, Hushmandi K, Ashrafizadeh M, Zarrabi A, Ertas YN, Mirzaei S, Samarghandian S. Entezari M, et al. Biomed Pharmacother. 2022 Feb;146:112563. doi: 10.1016/j.biopha.2021.112563. Epub 2021 Dec 29. Biomed Pharmacother. 2022. PMID: 35062059 Free article. Review.
Role of non-coding RNAs in osteoporosis.
Baniasadi M, Talebi S, Mokhtari K, Zabolian AH, Khosroshahi EM, Entezari M, Dehkhoda F, Nabavi N, Hashemi M. Baniasadi M, et al. Among authors: entezari m. Pathol Res Pract. 2024 Jan;253:155036. doi: 10.1016/j.prp.2023.155036. Epub 2023 Dec 13. Pathol Res Pract. 2024. PMID: 38134836 Review.
Non-coding RNAs and macrophage interaction in tumor progression.
Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Entezari M, et al. Crit Rev Oncol Hematol. 2022 May;173:103680. doi: 10.1016/j.critrevonc.2022.103680. Epub 2022 Apr 9. Crit Rev Oncol Hematol. 2022. PMID: 35405273 Review.
Targeting PI3K/Akt signaling in prostate cancer therapy.
Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S, Hejazi ES, Aboutalebi M, Gholamrezaie H, Saebfar H, Salimimoghadam S, Mirzaei S, Entezari M, Samarghandian S. Hashemi M, et al. Among authors: entezari m. J Cell Commun Signal. 2023 Sep;17(3):423-443. doi: 10.1007/s12079-022-00702-1. Epub 2022 Nov 11. J Cell Commun Signal. 2023. PMID: 36367667 Free PMC article. Review.
Non-coding RNA-based therapeutics in cancer therapy: An emphasis on Wnt/β-catenin control.
Taheriazam A, Bayanzadeh SD, Heydari Farahani M, Mojtabavi S, Zandieh MA, Gholami S, Heydargoy MH, Jamali Hondori M, Kangarloo Z, Behroozaghdam M, Khorrami R, Sheikh Beig Goharrizi MA, Salimimoghadam S, Rashidi M, Hushmandi K, Entezari M, Hashemi M. Taheriazam A, et al. Among authors: entezari m. Eur J Pharmacol. 2023 Jul 15;951:175781. doi: 10.1016/j.ejphar.2023.175781. Epub 2023 May 11. Eur J Pharmacol. 2023. PMID: 37179043 Review.
New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis.
Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Bahonar A, Nakhaee Z, Entezari M, Beig Goharrizi MAS, Salimimoghadam S, Ren J, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Tan SC, Hushmandi K. Sadrkhanloo M, et al. Among authors: entezari m. Pathol Res Pract. 2023 Nov;251:154902. doi: 10.1016/j.prp.2023.154902. Epub 2023 Oct 21. Pathol Res Pract. 2023. PMID: 37922723 Review.
103 results